Company news

OBI Pharma, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC

January 12, 2026

OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors

September 2, 2025

OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies

June 6, 2025

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADC

April 30, 2025

OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, and Globo H (GH) science

April 22, 2025

OBI Pharma Receives ‘Most Promising ADC Clinical Candidate in Taiwan’ Award

March 12, 2025

OBI Pharma Enters Collaboration with GlyTech to Expand GlycOBI® Enabling Technologies Outreach in Japan and to Advance Glycan Production

December 23, 2024

OBI Pharma announces Phase 1/2 study initiation for OBI-992, a TROP2-targeted antibody drug-Conjugate for cancer therapy

June 13, 2024

OBI Pharma Announces Phase 1/2 Study Initiation for OBI-992, a TROP2-Targeted Antibody-Drug Conjugate (ADC) for Cancer Therapy

June 12, 2024

OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform

March 18, 2024

Biosion's Partner OBI Pharma Announces FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992

January 9, 2024

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992

January 3, 2024

OBI Pharma Announces Executive Leadership Management Change – Heidi Wang, Ph.D. Appointed as Chief Executive Officer

June 2, 2023

OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy

April 10, 2023

Announcement on behalf of AP Biosciences to file application for Phase I human clinical trial of Bispecific Antibody, AP203, to US FDA

August 12, 2022

Announcement of amendment of the Company's 2021 Annual Report

August 11, 2022

Announcement that the cumulative reduction of shareholding in major subsidiary, AP Biosciences, has reached more than 10%

August 8, 2022

Announcement on behalf of AP Biosciences that preemptive rights forfeited by directors are over 50% and made available to specific persons

August 8, 2022

The Company’s BOD resolved to forfeit the subscription of AP Biosciences’ cash capital increase and distribute the rights to its shareholders

August 8, 2022

OBI Pharma forfeits subscription of AP Biosciences’ cash capital increase, distributes rights to its shareholders and sets target date

August 8, 2022

Decks

The 5 newest of 15 decks. Every deck is listed under its year.